Literature DB >> 6639006

Antibacterial activity of DL 473, a C3-substituted rifamycin derivative.

H C Neu.   

Abstract

DL 473 is a 3-[(4-cyclopentyl-1-piperazinyl)iminomethyl] rifamycin SV derivative which inhibited staphylococci, streptococci (including Streptococcus faecalis, Listeria species, and Bacteroides species. DL 473 was less active than rifampin against these species. DL 473 did not inhibit Enterobacteriaceae nor most Pseudomonas species. A combination of DL 473 and vancomycin or nafcillin tested against staphylococci was primarily additive and antagonism was not encountered.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6639006      PMCID： PMC185348          DOI： 10.1128/AAC.24.3.457

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  5 in total

1.  Studies of binding C3-substitute rifamycins to human and bovine serum albumin.

Authors:  A Assandri; A Perazzi; M Berti
Journal:  J Antibiot (Tokyo)       Date:  1977-05       Impact factor: 2.649

2.  Hydrazones of 3-formylrifamycin SV. I - Hydrazones with N-amino-N'-substituted piperazines: synthesis, antibacterial activity and other biological properties.

Authors:  R Cricchio; V Arioli; G C Lancini
Journal:  Farmaco Sci       Date:  1975-08

3.  Antibacterial activity in serum and urine following oral administration in man of DL473 (a cyclopentyl derivative of rifampicin) [proceedings].

Authors:  A T Birmingham; A J Coleman; M L Orme; B K Park; N J Pearson; A H Short; P J Southgate
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

4.  Activity of antimicrobials against Chlamydia trachomatis in vitro.

Authors:  G L Ridgway; J D Oriel
Journal:  J Antimicrob Chemother       Date:  1979-07       Impact factor: 5.790

5.  Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative.

Authors:  V Arioli; M Berti; G Carniti; E Randisi; E Rossi; R Scotti
Journal:  J Antibiot (Tokyo)       Date:  1981-08       Impact factor: 2.649
  5 in total
  4 in total

Review 1.  Rifamycins, Alone and in Combination.

Authors:  David M Rothstein
Journal:  Cold Spring Harb Perspect Med       Date:  2016-07-01       Impact factor: 6.915

Review 2.  Rifapentine.

Authors:  B Jarvis; H M Lamb
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

3.  In vitro activities of rifapentine and rifampin, alone and in combination with six other antibiotics, against methicillin-susceptible and methicillin-resistant staphylococci of different species.

Authors:  P E Varaldo; E Debbia; G C Schito
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

4.  A shorter treatment regimen for latent tuberculosis infection holds promise for at-risk Canadians.

Authors:  C Pease; K R Amaratunga; G G Alvarez
Journal:  Can Commun Dis Rep       Date:  2017-03-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.